Penatalaksanaan Terkini Penyakit Alzheimer
DOI:
https://doi.org/10.55175/cdk.v46i1.537Keywords:
Alzheimer, demensia, penyakit neurodegeneratifAbstract
Alzheimer atau demensia merupakan suatu penyakit neurodegeneratif yang terjadi pada usia lanjut (65 tahun ke atas) berupa penurunan daya ingat akibat deposisi plak beta amiloid di dalam otak. Terapi yang diberikan saat ini seperti asetilkolinesterase, masih inadekuat karena tidak spesifik terhadap target terapi yakni plak beta amiloid. Diperlukan terapi baru yang bekerja langsung pada target.
Alzheimer or dementia is a neurodegenerative disorder which often happened in the elderies (over 65 years old) with memory loss because of beta amyloid deposition in the brain. Current therapy such as acetylcholinesterase, still have inadequate response because that drug isn’t specific to therapeutic target, the beta amyloid plaque. A new therapy that acts directly to therapeutic target, is needed.
Downloads
References
Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50-6.
Schneider LS, Grundman M, Dekosky S, Morgan R, Guttendorf R, Higgin M, et al. The anti-Aβ oligomer drug CT1812 for Alzheimer’s: Phase 1b/2a safety trial outcomes [Internet]. 2017. Available from: http://cogrx.com/wp-content/uploads/2017/11/17-11-04-CTAD-CT1812-Late-Breaker-Oral-Presentation-Lon-Schneider-MD.pdf
Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, et al. Alzheimer’s therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate abeta 42 oligomer binding and synaptotoxicity. PLoS One. 2014;9(11):e111899.
Rehak C, Izzo N, Mozzoni K, Silky C, Yurko R, Safferstein H, et al. Sigma-2/PGRMC1 antagonist pharmacodynamics target engagement biomarker discovery for Alzheimer’s disease [Internet]. 2016. Available from: http://www.caprion.com/medias/doc/posters-papers/proteocarta/CogRX_2016_SFN_785.12_Biomarker_Poster.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.